Summary
The therapeutic effect of a new synthetic protease inhibitor on hemodynamic changes was studied in experimental acute pancreatitis. Pancreatitis was induced by the injection of autologous bile mixed with trypsin into the main pancreatic duct after ligating the accessory duct. Plasma beta-endorphin concentrations and cardiovascular function were measured. Seventeen dogs (control group) were given 10 ml/kg/hr of lactate Ringer’s solution intravenously 1 hr before the induction of pancreatitis and throughout the experiment. Seven dogs (the low protease inhibitor group) were given an intravenous bolus injection of 0.4mg/kg of a new synthetic protease inhibitor, E-3123 (4-(2-succiminido-ethylthio)4-geranidinobenzoate methanesulfate) 30 min after the induction of pancreatitis and then a continuous intravenous infusion at 3 Μg/kg/min throughout the experiment. Seven dogs (the high protease inhibitor group) received an intravenous bolus injection of 3 mg/kg and a continuous intravenous infusion at 50 Μg/kg/min of E-3123 according to the same method as in the low protease inhibitor group. The mortality rate during the experiment was 41% (7/17) in the control group, 28.5% (2/7) in the high protease inhibitor group and 0% in the low protease inhibitor group. The increase in the plasma beta-endorphin levels in the control group was statistically significant. When E-3123 was given 30 min after the induction of pancreatitis, the increase in the plasma beta-endorphin levels in the high protease inhibitor group was also found to be increased statistically significant, compared with preinduction levels, but the increase was statistically significantly lower than that in the control group. Plasma beta-endorphin levels in the low protease inhibitor group, however, did not increase. The protease inhibitor infusion as used in this experiment can bring about improvement in hypotension and myocardial depression to an extent by inhibiting the release of betaendorphin, suggesting that the inhibitory effect of the protease inhibitor on beta-endorphin release contributes to the improvement in hemodynamic changes during pancreatitis. There may also be an optimal therapeutic dose of this drug for the treatment of hypotension and myocardial depression secondary to betaendorphin release.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Elias E, Redshaw M, Wood T. Diagnostic importance of changes in circulations of immunoreactive trypsin. Lancet 1977;9:66–68.
Wellborn JC, Alston JD, Cannon DJ, Read RC: Serum proteolytic and antiproteolylic activity in acute pancreatitis. Am J Surg 1983;646:834–847.
Muramatsu M, Fujii S. Inhibitory effects of w-guanidine esters on trypsin plasmin, plasma kallikrein and thrombin. Biochem Biophys Acta 1972;268:221–224.
Tamura Y, Hirado M, Okamura K, et al. Synthetic inhibitors of trypsin, Plasmin, kallikrein, thrombin, C1 and1γ esterase. Biochem Biophys Acta 1977;484:417–422.
Fujii S, Hitomi Y. New synthetic inhibitors of C1 and C1γ esterase, thrombin, plasmin, kallikrein and trypsin. Biochem Biophys Acta 1981;661:342–345.
Trapnell JE, Rigby CC, Talbot CH, Duncan EHL. A control clinical trial of trasylol in the treatment of acute pancreatitis. Br J Surg 1974;61:177–182.
Satake K, Hiura A, Nishiwaki H, et al. Plasma beta-endorphin and the effect of naloxone on hemodynamic changes during experimental acute pancreatitis in dogs. Surg Gynecol & Obstet 1989; 168:402–406.
Kudo T, Maeda S, Nakamae J, et al. Changes of the Met-Enkepholin-like peptide content induced by noxious stimuli in the rat incisor pulp. Life Sci 1983;33:677–680.
—idem A possible relationship from precursor proteins to opioid peptides and noxious stimulation in the rat incisor pulp. Life Sci 1983;33:691–684.
Kudo T, Keeroi M, Inoki M. In vitro production and release of opioid peptides in the tooth pulp induced by bradykinin. Neuropeptide 1986;7:391–392.
Satake K, Hiura A, Ha S-S, et al. Effect of a new synthetic protease inhibitor on beta-endorphin release during acute pancreatitis in dogs. Pancreas 1991;6:441–447.
Miyamoto K, Hishinuma I, Nagakawa J, et al. Effect of E-3123, a new protease inhibitor, on several protease acute and on experimental acute pancreatitis. Folia Pharmacul Japan 1988;91:285–293.
Malfertheinor P. Somatostatin and protease inhibitors: Two Principle in treatment of acute pancreatitis. Proc. 4th meeting of International Association of Pancreatology 1990; 13. (Abstr)
Author information
Authors and Affiliations
Additional information
This work was supported in part by a grant-in-aid from the Japanese Ministry of Health and Welfare (Pancreatic Disease) and Grant 03670638 from the Japanese Ministry of Education, Science and Culture.
Rights and permissions
About this article
Cite this article
Satake, K., Ha, SS., Hiura, A. et al. The therapeutic effect of a new synthetic protease inhibitor (E-3123) on hemodynamic changes during experimental acute pancreatitis in dogs. Gastroenterol Jpn 28, 64–71 (1993). https://doi.org/10.1007/BF02775005
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02775005